Constitutive inflammation and epithelial-mesenchymal transition dictate sensitivity to nivolumab in CONFIRM: a placebo-controlled, randomised phase III trial
CONFIRM:一项安慰剂对照、随机 III 期试验表明,构成性炎症和上皮-间质转化决定了对纳武利尤单抗的敏感性。
期刊:Nature Communications
影响因子:15.7
doi:10.1038/s41467-025-61691-4
Fennell, Dean A; Hill, Kayleigh; Zhang, Min; Poile, Charlotte; Ewings, Sean; Baitei, Essa Y; Dzialo, Joanna; Nusrat, Nada; Rogel, Jan; Faulkner, Daniel; Ottensmeier, Christian; Califano, Raffaele; Hanna, Gerard G; Danson, Sarah; Steele, Nicola; Nye, Mavis; Johnson, Lucy; Mallard, Kim; Lord, Joanne; Middleton, Calley; Szlosarek, Peter; Chan, Sam; Darlison, Liz; Wells-Jordan, Peter; Richards, Cathy; Harber, James; Bzura, Aleksandra; Spicer, Jake; Pritchard, Catrin; Kamata, Tamihiro; Hahne, Jens C; Jama, Maymun; Hollox, Edward J; Lester, Jason F; Luo, Jin-Li; Zhou, Zisen; Yang, Hongji; Zhou, Huiyu; Klampatsa, Astero; Griffiths, Gareth O